uniQure (QURE) Research & Development (2016 - 2026)
uniQure (QURE) posted quarterly Research & Development of $34.0 million for Q2 2026, down 4.01% year-over-year from $35.4 million in Q2 2025, and up 16.41% quarter-over-quarter from $29.2 million in Q1 2026.
uniQure (QURE) Research & Development (2016 - 2026) Analysis & Trends
uniQure's Research & Development history runs 11 years deep, the most recent figure standing at $34.0 million for Q2 2026.
- In Q2 2026, Research & Development fell 4.01% year-over-year to $34.0 million; the TTM figure through Jun 2026 stood at $132.3 million (down 6.15% YoY), while the FY2025 annual figure was $140.7 million, down 2.16% from the prior year.
- Research & Development for Q2 2026 stood at $34.0 million, up from $29.2 million in the prior quarter.
- The five-year high for Research & Development was $65.4 million in Q3 2023, with the low at $29.2 million in Q1 2026.
- The 5-year median for Research & Development is $39.8 million (2024), against an average of $42.2 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development surged 41.06% in 2022, then slumped 53.22% in 2024.
- uniQure's Research & Development stood at $58.3 million in 2022, then declined by 26.93% to $42.6 million in 2023, then retreated by 8.87% to $38.8 million in 2024, then retreated by 10.44% to $34.8 million in 2025, then fell by 2.36% to $34.0 million in 2026.
- Business Quant data shows QURE's Research & Development at $34.0 million in Q2 2026, $29.2 million in Q1 2026, and $34.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | uniQure | 3.37 Bn | 3.37 Bn | 5.49 Mn | 33.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.96 Mn |
| Mar 31, 2026 | 29.18 Mn |
| Dec 31, 2025 | 34.78 Mn |
| Sep 30, 2025 | 34.37 Mn |
| Jun 30, 2025 | 35.38 Mn |
| Mar 31, 2025 | 36.14 Mn |
| Dec 31, 2024 | 38.84 Mn |
| Sep 30, 2024 | 30.60 Mn |
| Jun 30, 2024 | 33.66 Mn |
| Mar 31, 2024 | 40.69 Mn |
| Dec 31, 2023 | 42.62 Mn |
| Sep 30, 2023 | 65.40 Mn |
| Jun 30, 2023 | 46.04 Mn |
| Mar 31, 2023 | 60.81 Mn |
| Dec 31, 2022 | 58.33 Mn |
| Sep 30, 2022 | 48.07 Mn |
| Jun 30, 2022 | 46.19 Mn |
| Mar 31, 2022 | 45.00 Mn |
| Dec 31, 2021 | 42.34 Mn |
| Sep 30, 2021 | 36.43 Mn |